Trials / Completed
CompletedNCT02754141
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 235 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMS-986179 | Specified dose on specified days |
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| BIOLOGICAL | rHuPH20 | Specified dose on specified days |
Timeline
- Start date
- 2016-06-21
- Primary completion
- 2021-10-12
- Completion
- 2021-10-12
- First posted
- 2016-04-28
- Last updated
- 2023-04-05
- Results posted
- 2023-04-05
Locations
24 sites across 7 countries: United States, Australia, Canada, France, Germany, Italy, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02754141. Inclusion in this directory is not an endorsement.